Clinical trial NCT02974114: Exploratory Study to Investigate Cognition Function and Mobility in Individuals With Pain
Official title: Assessment of Cognitive Function and Mobility in Individuals With Pain
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Pain
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2016-11-28
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This parallel, assessor blind, placebo-controlled, stratified, randomized study will investigate the effects of everyday pain on cognition and mobility in otherwise healthy individuals.

Detailed description: This study consisted of 3 visits. Visit 1 (Day1, Screening), minimum (min) of 7 days and maximum (max) of 28 days gap followed by Visit 2 (Day 2, pain-state assessment), a recovery period of min of 2 days and max of 30 days followed by Visit 3 (Day 3, pain-free assessment). Participants received treatment once only on Visit 2.

Eligibility criteria: Inclusion Criteria

* Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
* Aged between 18-65 years.
* Participant is male or female.
* Understands and is willing, able and likely to comply with all study procedures and restrictions.
* Adequately completes cognition and mobility familiarisation tasks in the opinion of the investigator.
* Good general and mental health with, in the opinion of the investigator or medically qualified designee: No clinically significant and relevant abnormalities in medical history or upon physical examination; absence of any condition that might impact on the participant's safety or wellbeing or affect the individual's ability to understand and follow study procedures and requirements; BMI \>18.5 and \<30 kg/m2
* VISIT 1 ONLY - Has experienced a minimum of two recurrent, acute pain episodes within the past 3 months or is currently suffering from a flare up episode of recurrent, acute pain; VISIT 2 ONLY - A score ≥5 to question 6 (rated on scale 0-10) on the Brief Pain Inventory - Short Form and participants presenting with only one of the following pain types: Joint (Knee, Hip); Back; Headache; Period.

Exclusion Criteria

* Women who are pregnant (Visit 1), women of child bearing potential who test positive on a urine pregnancy test (Visit 1 or Visit 2), females of non-child bearing potential will not be required to complete urinary pregnancy test, post-menopausal females not requiring a pregnancy test will be defined as: Age ≥ 50 years with spontaneous cessation of menses for 12 or more months or age \< 55 years and spontaneous menses within the past 1 year, but currently amenorrheic.
* Women who are currently breast-feeding.
* In the opinion of the medical designee, participant suffers from medical condition(s) that may be aggravated due to testing procedures or may impact the interpretation or integrity of data. Conditions related to renal, hepatic, respiratory, blood, immune systems or heart dysfunction will be considered.
* Participant is colour blind.
* Current (within 14 days of the start of the study) or regular use of any prescription, over-the-counter (OTC), herbal medicine unless the medication has been approved by the study physician. OTC analgesics for pain relief and vitamin supplements are permitted only until 48 hours prior to study visits; Current or in the 30 days prior to dosing use of any drug, food, herbal product, or dietary supplement known to induce or inhibit hepatic drug metabolism (e.g. barbiturates, theophylline, cimetidine, or erythromycin) ;Use of analgesics and anti-inflammatory drugs 48 hours prior to dosing at Visit 2; Known to be taking any other medication which could counteract with paracetamol and/or caffeine; Current or past use of anti-depressants or psychoactive drugs within the previous 2-years.
* Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
* Positive breath alcohol test at Visit 2 and positive urine drugs of abuse test at Visit 2.
* Participation in another clinical study (including cosmetic studies) or receipt of an investigational product within 7 days of the screening visit or previous participation and randomization in this study.
* Participant has excessive frequent caffeine intake equivalent to 6 cups of brewed coffee or 12 cups of tea per day; Unwilling to abstain from any caffeine products from 4 hours prior to the visit on assessment days (Visit 2 and 3); Current Smoker (or regular nicotine consumption): Participant smokes more than 3 cigarettes per day (or equivalent for e-cigarettes, chewing tobacco or pipes). Investigator will ensure there is no impact of withdrawal effect from those with nicotine dependence; Current Alcohol Consumer: Participant consumes greater than 21 units of alcohol per week (male) and 14 units per week (female) (e.g. Spirit 25ml = 1 unit / AlcoPop 275ml = 1.5 unit / Bottle of beer 330 ml = 1.7 unit / Glass of wine 175ml = 2.1 unit / Pint of beer 568 ml = 3 unit).
* Members of the study site staff or members of their immediate family.
* Any participant who in the opinion of the investigator should not take part in this study.

Primary outcomes:
measure: Change From Pain Free State (Day 3) in Error Adjusted Simple Reaction Time (SRT) in the Pain State (Day 2)
timeFrame: At Day 2 (pre and post-treatment) and Day 3 of the study
measure: Change From Pain-free State (Day 3) in Reaction Time in the Pain State (Day 2)
timeFrame: At Day 2 (pre and post-treatment) and Day 3 of the study
measure: Change From Pain-free State (Day 3) in Number of One Touch Stockings (OTS) of Cambridge Assessment Problems (on Which the First Box Choice Made Was Correct) in the Pain State (Day 2)
timeFrame: At Day 2 (pre and post treatment) and Day 3 of the study
measure: Change From Pain-free State (Day 3) in Attention Switching Task (AST) Congruency Cost in the Pain State (Day 2)
timeFrame: At Day 2 (pre and post treatment) and Day 3 of the study
measure: Change From Pain-free State (Day 3) in Spatial Working Memory (SWM) Between Errors in the Pain State (Day 2)
timeFrame: At Day 2 (pre and post treatment) and Day 3 of the study
measure: Change From Pain-free State (Day 3) in Rapid Visual Information Processing A Prime (RVPA) in the Pain State (Day 2)
timeFrame: At Day 2 (pre and post treatment) and Day 3 of the study
Secondary outcomes:
measure: Change From Pain-free State (Day 3) in Grip Force in Pain State (Day 2)
timeFrame: At Day 2 (pre and post-treatment) and Day 3 of the study
measure: Change From Pain-free State (Day 3) in Time to Standing in Pain State (Day 2)
timeFrame: At Day 2 (pre and post treatment) and Day 3 of the study
measure: Change From Pain-free State (Day 3) in Ground Reaction Force (GRF) in Pain State (Day 2)
timeFrame: At Day 2 (pre and post treatment) and Day 3 of the study
measure: Change From Pain-free State (Day 3) in Contact Phase in Pain State (Day 2)
timeFrame: At Day 2 (pre and post treatment) and Day 3 of the study
measure: Change From Pain-free State (Day 3) in Stride Length in Pain State (Day 2)
timeFrame: At Day 2 (pre and post treatment) and Day 3 of the study
measure: Change From Pain-free State (Day 3) in Walking Speed in Pain State (Day 2)
timeFrame: At Day 2 (pre and post-treatment) and Day 3
Other outcomes:
Locations:
city: Brentford
country: United Kingdom
facility: GSK Investigational Site
state: Middlesex
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: